abstract gray background

Search Results

Found 36 results for label/kegiatan.

PPD | Our Solutions
Regulatory Affairs for FSP

PPD FSP regulatory affairs solutions help navigate regulatory approval and market access with comprehensive end-to-end regulatory services.

Read More
PPD | Post
New European Union Regulation to Change How Clinical Trials are Conducted

Our experts explain what is changing and how to prepare for and navigate the transition to the EU Clinical Trials Regulation (EU CTR).

Read More
PPD | Post
Real-World Data’s Role in Solving for Diversity in Clinical Research

Learn how using RWD and RWE to supplement trials provides understanding of safety and efficacy and effective off-label use.

Read More
PPD | Post
Regulatory Insights: Regulatory Intelligence Informs Sound Clinical Trial Strategy

Discover how Regulatory Intelligence is used in the pharmaceutical product development process through helping to formulate clinical trial success.

Read More
PPD | Post
The Complementary Roles of Wearables and Patient-Reported Outcomes in Patient-Focused Drug Development: Spotlight on Oncology Trials

Researchers incorporating wearables into their work should think of them as complementing — rather than replacing — insights from PROs.

Read More
PPD | Post
Success Factors for eCTD Implementation in Mainland China and Taiwan

Our experts discuss advances for eCTD implementation in mainland China and Taiwan and detail three critical success factors for readiness.

Read More
PPD | Post
Devices/Diagnostics: Emergency Use Authorizations During the COVID-19 Pandemic

Learn more about the increased uptake of Emergency Use Authorizations (EUA) for medical devices during the COVID-19 pandemic.

Read More
PPD | Post
Key Considerations for Successfully Planning a Submission

Learn the importance of strategy formulation and regulatory engagement for planning a successful ISS/ISE submission.

Read More
PPD | Our Solutions
Peri and Post-Approval

Biopharmaceutical companies are needing more and more evidence to prove value and effectiveness in post-approval settings, including how to communicate this evidence to payers, health authorities and other decision-makers.

Read More